Esther Krofah
Esther Krofah is the executive vice president of Health at the Milken Institute, leading FasterCures, Public Health, the Future of Aging, and Feeding Change. A recognized expert in health policy, biomedical innovation, and clinical research, Krofah has extensive experience shaping health initiatives that unite diverse stakeholders, foster collaboration, and motivate action toward shared goals. Under her leadership, the Milken Institute has formed multisectoral coalitions with hundreds of participating organizations to advance clinical trials through the Enabling Networks of Research Infrastructure for Community Health Through Clinical Trials (ENRICH-CT), Project Prevent, and the Milken Institute Women’s Health Network.
Before joining the Milken Institute, Krofah was the director of public policy at GlaxoSmithKline, where she led engagement with the US Department of Health and Human Services (HHS) and relevant executive-branch agencies. She also served as a political appointee to President Obama as deputy director of HHS’s Office of Health Reform, led health policy work with state governments at the National Governors Association, and worked in management consulting at Deloitte Consulting LLP. Krofah received a BA from Duke University and a master’s in public policy from Harvard University’s John F. Kennedy School of Government.
Krofah is an active member of several advisory boards informing work on health policy, innovation, and effective multistakeholder strategies for health transformation. She is the immediate past president of the Alliance for a Stronger FDA, a member of the National Academy of Medicine Drug Forum, a member of the editorial advisory board for Therapeutic Innovation & Regulatory Science (TIRS), the official journal of the Drug Information Association, and a member of the boards of the Clinical Trials Transformation Initiative (CTTI), Duke Margolis Institute for Health Policy, Eshelman Institute for Innovation, i-Cubed Duke Clinical Research Institute, Global Liver Institute, Medical Device Industry Consortium (MDIC), Protas, Reagan-Udall Foundation for the FDA, and Seed Global Health.
